Arizona State Retirement System grew its stake in Diplomat Pharmacy Inc (NYSE:DPLO) by 226.7% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 81,033 shares of the company’s stock after buying an additional 56,233 shares during the period. Arizona State Retirement System’s holdings in Diplomat Pharmacy were worth $1,626,000 at the end of the most recent reporting period.

A number of other hedge funds also recently added to or reduced their stakes in DPLO. SG Americas Securities LLC purchased a new stake in shares of Diplomat Pharmacy in the 3rd quarter valued at $191,000. Piedmont Investment Advisors LLC purchased a new stake in shares of Diplomat Pharmacy in the 3rd quarter valued at $216,000. Fox Run Management L.L.C. purchased a new stake in shares of Diplomat Pharmacy in the 4th quarter valued at $244,000. Invictus RG boosted its stake in shares of Diplomat Pharmacy by 24.4% in the 3rd quarter. Invictus RG now owns 13,820 shares of the company’s stock valued at $286,000 after purchasing an additional 2,707 shares in the last quarter. Finally, D.A. Davidson & CO. purchased a new stake in shares of Diplomat Pharmacy in the 4th quarter valued at $278,000. 64.62% of the stock is owned by institutional investors and hedge funds.

How to Become a New Pot Stock Millionaire

Shares of Diplomat Pharmacy Inc (NYSE DPLO) opened at $22.45 on Wednesday. The firm has a market cap of $1,540.00, a price-to-earnings ratio of 66.03 and a beta of 1.32. The company has a current ratio of 0.97, a quick ratio of 0.66 and a debt-to-equity ratio of 0.70. Diplomat Pharmacy Inc has a 12-month low of $14.00 and a 12-month high of $27.78.

Diplomat Pharmacy (NYSE:DPLO) last announced its quarterly earnings results on Monday, February 26th. The company reported $0.18 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.16 by $0.02. The business had revenue of $1.16 billion during the quarter, compared to analysts’ expectations of $1.17 billion. Diplomat Pharmacy had a net margin of 0.35% and a return on equity of 8.89%. The firm’s revenue for the quarter was up .9% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.08 EPS. equities research analysts expect that Diplomat Pharmacy Inc will post 0.93 earnings per share for the current fiscal year.

In other Diplomat Pharmacy news, Director Philip R. Hagerman sold 2,150,000 shares of the stock in a transaction on Friday, March 9th. The shares were sold at an average price of $20.65, for a total transaction of $44,397,500.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Corporate insiders own 30.20% of the company’s stock.

A number of equities research analysts have recently issued reports on the stock. Barclays assumed coverage on shares of Diplomat Pharmacy in a research note on Thursday, March 8th. They issued an “overweight” rating and a $27.00 price objective for the company. Deutsche Bank cut shares of Diplomat Pharmacy from a “buy” rating to a “hold” rating and upped their price objective for the company from $22.00 to $29.00 in a research note on Friday, February 2nd. Robert W. Baird cut shares of Diplomat Pharmacy from an “outperform” rating to a “neutral” rating and cut their price objective for the company from $24.00 to $18.00 in a research note on Thursday, November 16th. Lake Street Capital assumed coverage on shares of Diplomat Pharmacy in a research note on Friday, February 9th. They issued a “buy” rating and a $35.00 price objective for the company. Finally, Credit Suisse Group raised shares of Diplomat Pharmacy from an “underperform” rating to a “neutral” rating and set a $28.00 price objective for the company in a research note on Thursday, January 25th. Eight research analysts have rated the stock with a hold rating and five have given a buy rating to the stock. Diplomat Pharmacy has a consensus rating of “Hold” and an average target price of $25.38.

TRADEMARK VIOLATION WARNING: This story was published by Daily Political and is owned by of Daily Political. If you are reading this story on another domain, it was illegally copied and republished in violation of United States & international trademark and copyright legislation. The correct version of this story can be accessed at https://www.dailypolitical.com/2018/03/14/arizona-state-retirement-system-grows-holdings-in-diplomat-pharmacy-inc-dplo.html.

Diplomat Pharmacy Company Profile

Diplomat Pharmacy, Inc (Diplomat) operates a specialty pharmacy business, which stocks, dispenses and distributes prescriptions for various biotechnology and specialty pharmaceutical manufacturers. The Company operates through specialty pharmacy services segment. The Company’s primary focus is on medication management programs for individuals with chronic diseases, including oncology, immunology, hepatitis, multiple sclerosis, specialty infusion therapy, and various other serious and/or long-term conditions.

Want to see what other hedge funds are holding DPLO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Diplomat Pharmacy Inc (NYSE:DPLO).

Institutional Ownership by Quarter for Diplomat Pharmacy (NYSE:DPLO)

Receive News & Ratings for Diplomat Pharmacy Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diplomat Pharmacy and related companies with MarketBeat.com's FREE daily email newsletter.